Back Cover: Circulating genomic biomarkers predict chemoradiotherapy resistance and immunotherapy response in locally advanced non-small-cell lung cancer (View 3/2025)

In this article, the authors demonstrate that circulating tumor DNA (ctDNA)-based genomic features can predict efficacy of chemoradiotherapy and immunotherapy in patients with unresectable locally advanced non-small-cell lung cancer. Blood-based STK11/KEAP1 mutations are associated with poor prognosis and resistance to definitive chemoradiotherapy, but suggest benefits from consolidation immunotherapy. This integrative biomarker strategy of combining post-treatment ctDNA molecular residual disease detection with pre-treatment STK11/KEAP1 mutations effectively enhances predictive sensitivity, offering a promising approach for personalized therapeutic decisions.